共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 当前对原发性肝癌治疗的新认识显示文摘在全球常见的癌症中,原发性肝癌(HCC)发病率排名第五位,是第三大由癌症而致死的常见原因[1]。外科手术切除(HR)、局部消融治疗和肝移植(LT)被认为是有治愈可能的措施。但据估计,手术切除或射频消融(RFA)仅对10%的肝癌患者有明显疗效,且这部分患者的肿瘤直径≤3 cm[2];据报道,直到上世纪90年代中期,肝移植患者5年生存率仅为30%~40%。 | 冀春亮 赵卫 | 2012 | 山东医药2012，52，7： | 11 |
| 2 | Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma显示文摘AIM: To elucidate the relationship between the microvessel count (MVC) by CD34 analyzed by immunohistochemical method and prognosis in hepatocellular carcinoma (HCC) patients who underwent hepatectomy based on our preliminary study. METHODS: We examined relationships between MVC and clinicopathological factors in 128 HCC patients. The modifi ed Japan Integrated Staging score (mJIS) was applied to examine subsets of HCC patients. RESULTS: Median MVC was 178/mm^2, which was used as a cut-off value. MVC was not signif icantly associated with any clinicopathologic factors or postoperative recurrent rate. Lower MVC was associated with poor disease-free and overall survivals by univariate analysis (P = 0.039 and P = 0.087, respectively) and lower MVC represented an independent poor prognostic factor in disease-free survival by Cox’s multivariateanalysis (risk ratio, 1.64; P = 0.024), in addition to tumor size, vascular invasion, macroscopic fi nding and hepatic dysfunction. Signifi cant differences in disease-free and overall survivals by MVC were observed in HCC patients with mJIS 2 (P = 0.046 and P = 0.0014, respectively), but not in those with other scores. CONCLUSION: Tumor MVC appears to offer a useful prognostic marker of HCC patient survival, particularly in HCC patients with mJIS 2. | Atsushi Nanashima Toshiyuki Nakayama Yorihisa Sumida Takafumi Abo Hiroaki Takeshita Kenichirou Shibata Shigekazu Hidaka Terumitsu Sawai Toru Yasutake Takeshi Nagayasu | 2008 | World Journal of Gastroenterology2008，14，31： | 7 |
您所在的机构暂未开通此部分的功能，请联系管理员